Results 81 to 90 of about 331,051 (308)

Retracted: Clinical Observation of MRI Scanning Combined with Clinical Nursing for Surgical Breast Cancer Patients

open access: yesInternational Journal of Analytical Chemistry, 2023
International Journal of Analytical Chemistry
doaj   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

open access: yesMolecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert   +13 more
wiley   +1 more source

Retracted: The Research Progress in the Application of Ceramic Nanofibers in Antibacterial Textile Materials

open access: yesInternational Journal of Analytical Chemistry, 2023
International Journal of Analytical Chemistry
doaj   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser   +14 more
wiley   +1 more source

Retracted: Extraction and Dyeing Techniques of Traditional Vegetable Dyestuffs

open access: yesInternational Journal of Analytical Chemistry, 2023
International Journal of Analytical Chemistry
doaj   +1 more source

Editorial: Innovators in analytical chemistry. [PDF]

open access: yesFront Chem, 2023
Bala C   +3 more
europepmc   +1 more source

Analytical performance evaluation of the Biosystems BA400 Clinical Chemistry Analyzer

open access: green, 2015
Khanittha Taneyhill   +4 more
openalex   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy